Literature DB >> 23410974

Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia.

Cyrus Khandanpour1, James D Phelan, Lothar Vassen, Judith Schütte, Riyan Chen, Shane R Horman, Marie-Claude Gaudreau, Joseph Krongold, Jinfang Zhu, William E Paul, Ulrich Dührsen, Bertie Göttgens, H Leighton Grimes, Tarik Möröy.   

Abstract

Most patients with acute lymphoblastic leukemia (ALL) fail current treatments highlighting the need for better therapies. Because oncogenic signaling activates a p53-dependent DNA damage response and apoptosis, leukemic cells must devise appropriate countermeasures. We show here that growth factor independence 1 (Gfi1) can serve such a function because Gfi1 ablation exacerbates p53 responses and lowers the threshold for p53-induced cell death. Specifically, Gfi1 restricts p53 activity and expression of proapoptotic p53 targets such as Bax, Noxa (Pmaip1), and Puma (Bbc3). Subsequently, Gfi1 ablation cures mice from leukemia and limits the expansion of primary human T-ALL xenografts in mice. This suggests that targeting Gfi1 could improve the prognosis of patients with T-ALL or other lymphoid leukemias.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23410974      PMCID: PMC3597385          DOI: 10.1016/j.ccr.2013.01.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  49 in total

1.  Regulation of p53 function by lysine methylation.

Authors:  Lisandra E West; Or Gozani
Journal:  Epigenomics       Date:  2011-06       Impact factor: 4.778

2.  Zinc finger protein GFI-1 cooperates with myc and pim-1 in T-cell lymphomagenesis by reducing the requirements for IL-2.

Authors:  M Zörnig; T Schmidt; H Karsunky; A Grzeschiczek; T Möröy
Journal:  Oncogene       Date:  1996-04-18       Impact factor: 9.867

3.  Structurally distinct ligand-binding or ligand-independent Notch1 mutants are leukemogenic but affect thymocyte development, apoptosis, and metastasis differently.

Authors:  Elena Priceputu; Isabelle Bouallaga; YaoPing Zhang; Xiujie Li; Pavel Chrobak; Zaher S Hanna; Johanne Poudrier; Denis G Kay; Paul Jolicoeur
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

4.  Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma.

Authors:  Mondira Kundu; Sheila Compton; Lisa Garrett-Beal; Terryl Stacy; Matthew F Starost; Michael Eckhaus; Nancy A Speck; P Paul Liu
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

5.  Characterization of pal-1, a common proviral insertion site in murine leukemia virus-induced lymphomas of c-myc and Pim-1 transgenic mice.

Authors:  B Scheijen; J Jonkers; D Acton; A Berns
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

7.  Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues.

Authors:  Dorothe Hameyer; Ate Loonstra; Leonid Eshkind; Steffen Schmitt; Cecilia Antunes; Annemiek Groen; Eric Bindels; Jos Jonkers; Paul Krimpenfort; Ralph Meuwissen; Loes Rijswijk; Axel Bex; Anton Berns; Ernesto Bockamp
Journal:  Physiol Genomics       Date:  2007-04-24       Impact factor: 3.107

8.  p53 is regulated by the lysine demethylase LSD1.

Authors:  Jing Huang; Roopsha Sengupta; Alexsandra B Espejo; Min Gyu Lee; Jean A Dorsey; Mario Richter; Susanne Opravil; Ramin Shiekhattar; Mark T Bedford; Thomas Jenuwein; Shelley L Berger
Journal:  Nature       Date:  2007-09-06       Impact factor: 49.962

9.  Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein.

Authors:  C B Gilks; S E Bear; H L Grimes; P N Tsichlis
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

10.  DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours.

Authors:  J Bartkova; Z Horejsí; M Sehested; J M Nesland; E Rajpert-De Meyts; N E Skakkebaek; M Stucki; S Jackson; J Lukas; J Bartek
Journal:  Oncogene       Date:  2007-06-04       Impact factor: 9.867

View more
  43 in total

1.  Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia.

Authors:  Jixin Ding; Melissa L Fishel; April M Reed; Erin McAdams; Magdalena B Czader; Angelo A Cardoso; Mark R Kelley
Journal:  Mol Cancer Ther       Date:  2017-04-26       Impact factor: 6.261

2.  LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.

Authors:  Jessica Barth; Khalil Abou-El-Ardat; Denis Dalic; Nina Kurrle; Anna-Maria Maier; Sebastian Mohr; Judith Schütte; Lothar Vassen; Gabriele Greve; Johannes Schulz-Fincke; Martin Schmitt; Milica Tosic; Eric Metzger; Gesine Bug; Cyrus Khandanpour; Sebastian A Wagner; Michael Lübbert; Manfred Jung; Hubert Serve; Roland Schüle; Tobias Berg
Journal:  Leukemia       Date:  2019-01-24       Impact factor: 11.528

3.  IGFBP7 activates retinoid acid-induced responses in acute myeloid leukemia stem and progenitor cells.

Authors:  Noortje van Gils; Han J M P Verhagen; Arjo Rutten; Renee X Menezes; Mei-Ling Tsui; Eline Vermue; Esmée Dekens; Fabio Brocco; Fedor Denkers; Floortje L Kessler; Gert J Ossenkoppele; Jeroen J W M Janssen; Linda Smit
Journal:  Blood Adv       Date:  2020-12-22

4.  GFI1 is required for RUNX1/ETO positive acute myeloid leukemia.

Authors:  Anna E Marneth; Lacramioara Botezatu; Judith M Hönes; Jimmy C L Israël; Judith Schütte; Lothar Vassen; Robert F Lams; Saskia M Bergevoet; Laura Groothuis; Amit Mandoli; Joost H A Martens; Gerwin Huls; Joop H Jansen; Ulrich Dührsen; Tobias Berg; Tarik Möröy; Christian Wichmann; Mia-Chia Lo; Dong-Er Zhang; Bert A van der Reijden; Cyrus Khandanpour
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

5.  Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.

Authors:  Aravinda Kuntimaddi; Nicholas J Achille; Jeremy Thorpe; Alyson A Lokken; Ritambhara Singh; Charles S Hemenway; Mazhar Adli; Nancy J Zeleznik-Le; John H Bushweller
Journal:  Cell Rep       Date:  2015-04-23       Impact factor: 9.423

6.  RasGRP Ras guanine nucleotide exchange factors in cancer.

Authors:  Olga Ksionda; Andre Limnander; Jeroen P Roose
Journal:  Front Biol (Beijing)       Date:  2013-10-01

7.  SON and Its Alternatively Spliced Isoforms Control MLL Complex-Mediated H3K4me3 and Transcription of Leukemia-Associated Genes.

Authors:  Jung-Hyun Kim; Melody C Baddoo; Eun Young Park; Joshua K Stone; Hyeonsoo Park; Thomas W Butler; Gang Huang; Xiaomei Yan; Florencia Pauli-Behn; Richard M Myers; Ming Tan; Erik K Flemington; Ssang-Taek Lim; Eun-Young Erin Ahn
Journal:  Mol Cell       Date:  2016-03-17       Impact factor: 17.970

8.  A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia.

Authors:  Yun Tan; Xiaoling Wang; Huan Song; Yi Zhang; Rongsheng Zhang; Shufen Li; Wen Jin; Saijuan Chen; Hai Fang; Zhu Chen; Kankan Wang
Journal:  Blood       Date:  2021-03-18       Impact factor: 22.113

Review 9.  From cytopenia to leukemia: the role of Gfi1 and Gfi1b in blood formation.

Authors:  Tarik Möröy; Lothar Vassen; Brian Wilkes; Cyrus Khandanpour
Journal:  Blood       Date:  2015-10-07       Impact factor: 22.113

10.  GFI1 as a novel prognostic and therapeutic factor for AML/MDS.

Authors:  J M Hönes; L Botezatu; A Helness; C Vadnais; L Vassen; F Robert; S M Hergenhan; A Thivakaran; J Schütte; Y S Al-Matary; R F Lams; J Fraszscak; H Makishima; T Radivoyevitch; B Przychodzen; S V da Conceição Castro; A Görgens; B Giebel; L Klein-Hitpass; K Lennartz; M Heuser; C Thiede; G Ehninger; U Dührsen; J P Maciejewski; T Möröy; C Khandanpour
Journal:  Leukemia       Date:  2016-02-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.